Pharmacological blockade of TRPV1 receptors modulates the effects of 6-OHDA on motor and cognitive functions in a rat model of parkinson's disease

Fundamental and Clinical Pharmacology

Volumn 27, Issue 6, 2013, Pages 632-640

  Razavinasab, Moazamehosadat ^a   Shamsizadeh, Ali ^a   Shabani, Mohammad ^b   Nazeri, Masoud ^c   Allahtavakoli, Mohammad ^a   Asadi Shekaari, Majid ^b   Esmaeli Mahani, Saeed ^d   Sheibani, Vahid ^b  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BAHONAR UNIVERSITY OF KERMAN   (Iran)

Author keywords

6 Hydroxydopamine; AMG; Cognitive function; Motor function

Indexed keywords

CANNABINOID RECEPTOR; N (1,4 BENZODIOXAN 6 YL) 3 (4 TERT BUTYLPHENYL)ACRYLAMIDE; OXIDOPAMINE; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CHRONIC DRUG ADMINISTRATION; COGNITION; CONTROLLED STUDY; HYPOKINESIA; LEARNING DISORDER; MALE; MEMORY DISORDER; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTAROD TEST; SINGLE DRUG DOSE;

6- HYDROXYDOPAMINE; AMG; COGNITIVE FUNCTION; MOTOR FUNCTION;

ACRYLAMIDES; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; COGNITION; DISEASE MODELS, ANIMAL; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; TRPV CATION CHANNELS;

EID: 84886591048     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12015     Document Type: Article

References (28)

1. Marzo V.D., Starowicz K., Cristino L. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr. Pharm. Des. (2008) 14 42-54.
2. Kark T., Bagi Z., Lizanecz E. et al. Tissue-specific regulation of microvascular diameter: opposite functional roles of neuronal and smooth muscle located vanilloid receptor-1. Mol. Pharmacol. (2008) 73 1405-1412.
3. Bennion D., Jensen T., Walther C. et al. Transient receptor potential vanilloid 1 agonists modulate hippocampal CA1 LTP via the GABAergic system. Neuropharmacology (2011) 61 730-738.
4. Avelino A., Cruz F. TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications. Naunyn-Schmiedeberg's Arch. Pharmacol. (2006) 373 287-299.
5. Mezey É., Tóth Z.E., Cortright D.N. et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl Acad. Sci. (2000) 97 3655.
6. Marinelli S., Di Marzo V., Berretta N. et al. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J. Neurosci. (2003) 23 3136-3144.
7. Kim S.R., Chung Y.C., Chung E.S. et al. Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity. Mol. Neurobiol. (2007) 35 245-254.
8. Di Marzo V., Lastres-Becker I., Bisogno T. et al. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur. J. Pharmacol. (2001) 420 123-131.
9. de Lago E., de Miguel R., Lastres-Becker I., Ramos J.A., Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res. (2004) 1007 152-159.
10. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., Brotchie A.R. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. (2000) 14 1432-1438.
11. Gubellini P., Picconi B., Bari M. et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. (2002) 22 6900-6907.
12. Lastres-Becker I., De Miguel R., De Petrocellis L., Makriyannis A., Di Marzo V., Fernández-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J. Neurochem. (2003) 84 1097-1109.
13. Kim S.R., Lee D.Y., Chung E.S., Oh U.T., Kim S.U., Jin B.K. Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J. Neurosci. (2005) 25 662-671.
14. Rodríguez Díaz.M., Abdala P., Barroso-Chinea P., Obeso J., González-Hernández T. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav. Brain Res. (2001) 122 79-92.
15. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, 5th edn, Academic Press, New York, 2005.
16. Shabani M.L.M., Parsania S., Hajali V., Shojaei A. Evaluation of destructive effects of exposure to cisplatin during developmental stage: no profound evidence for sex differences in impaired motor and memory performance. Int. J. Neurosci. (2012) 122 439-448.
17. Shabani M., Hosseinmardi N., Haghani M., Shaibani V., Janahmadi M. Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurones in rat offspring. Neuroscience (2011) 172 139-152.
18. Shabani M., Larizadeh M.H., Parsania S., Asadi Shekaari M., Shahrokhi N. Profound destructive effects of adolescent exposure to vincristine accompanied with some sex differences in motor and memory performance. Can. J. Physiol. Pharmacol. (2012) 90 379-386.
19. Haghani M., Shabani M., Javan M., Motamedi F., Janahmadi M. CB1 cannabinoid receptor activation rescues amyloid β-induced alterations in behaviour and intrinsic electro-physiological properties of rat hippocampal CA1 pyramidal neurones. Cell. Physiol. Biochem. (2012) 29 391-406.
20. Hanagasi H.A., Emre M. Treatment of behavioural symptoms and dementia in Parkinson's disease. Fundam. Clin. Pharmacol. (2005) 19 133-146.
21. Levy G., Tang M.X., Louis E. et al. The association of incident dementia with mortality in PD. Neurology (2002) 59 1708-1713.
22. Kim S.R., Kim S.U., Oh U., Jin B.K. Transient receptor potential vanilloid subtype 1 mediates microglial cell death in vivo and in vitro via Ca2 + -mediated mitochondrial damage and cytochrome c release. J. Immunol. (2006) 177 4322-4329.
23. Devos D., Defebvre L., Bordet R. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease. Fundam. Clin. Pharmacol. (2010) 24 407-421.
24. Spinnewyn B., Charnet C., Cornet S., Roubert V., Chabrier P.E., Auguet M. An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats. Fundam. Clin. Pharmacol. (2011) 25 608-618.
25. Hu D.E., Easton A.S., Fraser P.A. TRPV1 activation results in disruption of the blood-brain barrier in the rat. Br. J. Pharmacol. (2005) 146 576-584.
26. Pan J.P., Zhang H.Q., Guo Y.F., Cao X.H., Liu L.J. Some subtypes of endocannabinoid/endovanilloid receptors mediate docosahexaenoic acid-induced enhanced spatial memory in rats. Brain Res. (2011) 1412 18-27.
27. Cristino L., De Petrocellis L., Pryce G., Baker D., Guglielmotti V., Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience (2006) 139 1405-1415.
28. Li H.B., Mao R.R., Zhang J.C., Yang Y., Cao J., Xu L. Antistress effect of TRPV1 channel on synaptic plasticity and spatial memory. Biol. Psychiatry (2008) 64 286-292.